Allan Robins, Ph.D. was appointed ViaCyte's Acting Chief Executive Officer in July 2011 and concurrently serves as Vice President and Chief Technical Officer. Prior to ViaCyte, Dr. Robins served as Chief Scientific Officer at BresaGen, Inc. and under his leadership, BresaGen, Inc. was awarded significant support for its stem cell research from the National Institutes of Health. Prior to BresaGen, Inc., Dr. Robins was Chief Scientific Officer at BresaGen Limited, where he helped raise over $30 million and developed a proprietary expression system which continues to be used in the production of protein pharmaceuticals.
Dr Robins’ P2T 2012 presentation will be titled ES Derived Islets to Treat Type I Diabetes
